PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is a Healthcare company (Medical - Devices) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
PROCEPT BioRobotics Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $23.78, PROCEPT BioRobotics Corporation trades at 3.9x sales and 4.1x book value. Over the last twelve months it generated about $353M of revenue and a net loss of $116M. It runs a gross margin of 64.7%, an operating margin of -33.6% and a net margin of -32.6%. It shows return on equity of -33.2%, return on invested capital of -29.2% and a free cash flow yield of -9.2%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 5.89. Over the past 52 weeks the share price ranged from $16.66 to $38.11, with a beta of 0.84.
PROCEPT BioRobotics Corporation does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 9 Buy, 7 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, PROCEPT BioRobotics Corporation (PRCT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.56% / 30% · (Cash+Inv) / Mkt Cap (36m) 19.3% / 30% · Interest income / Revenue 1.69% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 4.56% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 19.3% / 33% · Receivables / Mkt Cap (36m) 9.26% / 49% · Interest income / Revenue 1.69% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 4.56% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 19.3% / 33.33% · Receivables / Mkt Cap (24m) 9.26% / 33.33% · Interest income / Revenue 1.69% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 10.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 50.2% / 33.33% · Receivables / Avg Assets (4Q) 20.1% / 33.33% · Interest income / Revenue 1.69% / 5% | Fail |
| FTSE | Debt / Total Assets 10.9% / 33.33% · (Cash+ST Inv) / Total Assets 46.1% / 33.33% · (Cash+Recv) / Total Assets 68.3% / 33.33% · Interest income / Revenue 1.69% / 5% | Fail |
It depends on the standard you follow. As of September 2026, PROCEPT BioRobotics Corporation (PRCT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. PROCEPT BioRobotics Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.69% of each dividend: PROCEPT BioRobotics Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.